The First Cannabis IP-Licensing Company, Breeder’s Best, Officially Launches

New company brings together cannabis industry leaders including attorney-scientist Dale Hunt, researcher-physician Ethan Russo, and botanist-author Robert C. Clarke

CALIFORNIA: Cannabis industry pioneers, Dale Hunt, PhD, JD, Ethan Russo, MD, and Robert C. Clarke have joined forces to create Breeder’s Best, the first cannabis company to focus on intellectual property (IP) protection for independent plant breeders and licensing IP for access to markets worldwide. Breeder’s Best brings a global plant-licensing model, proven successful in other agriculture industries, to cannabis.

The liberalization of global cannabis laws and growing public acceptance of cannabis have created a rapidly escalating demand for cannabis flower, as well as therapeutics and products made with cannabis. According to a report by Prohibition Partners, the international cannabis industry is projected to grow to more than $103.6 billion by 2024.

While the cannabis industry presents significant opportunity, there exists a critical disconnect that separates the creativity of breeders from the markets that are demanding products with unique and proven genetic profiles. Additionally, there is typically very little IP protection to support good partnerships between breeders and cannabis brands. Breeder’s Best will connect these two key stakeholders while legally protecting the genetic inventiveness of breeders.

Breeder’s Best founder and CEO Dale Hunt says, “Our mission is to connect the best Cannabis genetics to the greatest needs and most promising commercial opportunities. To do that, we have assembled an unparalleled team of experts with deep experience at every level of the cannabis supply chain. As the industry matures, Breeder’s Best will be positioned to meet the demands of the increasingly professional and GMP-oriented marketplace while doing business in a way that benefits breeders and directs profitable and reliable business to growers who may otherwise be left behind. With our vision, team, model, know-how, and relationships, Breeder’s Best is poised to become the global leader in patented cannabis genetics and related products.” Dr. Hunt has been practicing IP law for 23 years. He has a PhD in plant cellular and molecular biology and has obtained thousands of patents and plant variety rights for his clients in more than 30 countries.

“Cannabis use is finally normalizing. At Breeder’s Best, we present independent Cannabis breeders the opportunity to protect their unique varieties and assist them in placing those genetics in lucrative markets. This is a great service to breeders who would prefer to focus on the art and science of breeding, instead of dealing with the mechanics of commercialization,” said Breeder’s Best Director of Agronomy and Genetics, Robert C. Clarke. Mr. Clarke is a 40-year cannabis industry veteran, revered for his books Marijuana Botany, published in 1982, and Cannabis: Evolution and Ethnobotany, published in 2013.

The Cannabis plant produces over 450 chemical components, many of which are potentially therapeutic. However, decades of cannabis prohibition have resulted in a lack of genetic diversity worldwide and a predominance of only a small fraction of potential agents.

“We have just begun to scratch the surface of everything that cannabis can do to improve and enhance our lives,” said Dr. Ethan Russo. “That’s what Breeder’s Best will do. Identifying, selectively breeding for and utilizing specific chemical components will truly transform medicine in the coming decades.” Dr. Russo is a board-certified neurologist, preeminent medical cannabis expert, author of more than 50 peer-reviewed medical journal articles and a veteran of GW Pharmaceuticals where he served as Senior Medical Advisor as well as the Sativex® and Epidiolex® clinical trial Study Physician and Medical Monitor.


About Breeder’s Best:  Breeder’s Best is a privately held Cannabis IP genetics company organized as a B Corporation to demonstrate our commitment to independent Cannabis breeders and to meeting the worldwide needs of patients and consumers for superior products. To learn more about Breeder’s Best visit www.breedersbest.com.

Hot Pot Stocks: Aurora Cannabis vs. GW Pharmaceuticals. Which Cannabis Stock To Buy?

By Cristine Felt 

Aurora Cannabis vs. GW Pharmaceuticals: Which Cannabis Stock To Buy?

In this time and age when cannabis industry is simply blooming, it appears even an inexperienced rookie could try their hand at buying cannabis stocks and shares without the slightest fear of losing. Indeed, the global market is thought to be worth some astonishing $150 billion, with the prognosis of hitting $272 billion by 2028. You may have envisioned that world popular “shut up and take my money” meme already, but it’s not that simple (as usual). Stocks rise and fall, so it’s best to rely on the companies that have been around for a while and are doing a pretty good job, to say the least – Aurora Cannabis and GW Pharmaceuticals.

But which one is a tad better? Let’s make a brief comparison.

Aurora-Cannabis-LogoAurora Cannabis

Aurora Cannabis is a Canadian cannabis producer which was founded in 2013. The company deals with the production and distribution of medical and recreational cannabis. Just saying their business is based in Canada speaks volumes. Ever since the country has legalized cannabis use in October last year, the sales have been rising, and it was excellent news for experienced players such as Aurora Cannabis.

They had a 20% market share in the last quarter of 2018. As one of the largest marijuana producers, and with expectations to produce astounding 500,000 kilograms in the near future, it appears they are a force to be reckoned with. Moreover, Aurora is Germany’s main cannabis supplier, and this European country is expected to follow Canada’s suit soon. In addition, it also exports products to 20 other countries in five continents. What is more, the announced shortage of cannabis supply is without a doubt an excellent opportunity for the company. Their latest market cap is $9.042B.

But, what about the drawbacks?

For one reason, their overall business in 2018 was not as stable as it may have seemed. Their general performance was quite disappointing, and they were listed as one of top five worst Canadian cannabis stocks. The last quarter turned out great due to the consequences of the messy legalization, which Aurora benefited from.

gwphGW Pharmaceuticals

On the other hand, we have a British biopharmaceutical company and a true pioneer in the industry. They are globally well-known due to a product of theirs called Sativex, an oral spray that is extensively used in the treatment of multiple sclerosis. They reaped huge success with it, and it is sold as a prescription drug in the UK, EU, New Zealand, Israel and Canada. GW Pharmaceuticals was set up in 1998, and their vast research experience is bearing fruit once again with the latest breakthrough in medical cannabis industry in the form of Epidiolex. In its essence, this drug is a purified CBD, and one of the reasons why Epidiolex is a revolutionary prescription drug is the fact that it was recently approved by the U.S. Food and Drug Administration for patients suffering from different types of seizure. Bearing in mind its CBD content, this is definitely an unprecedented event. Obviously, the company has made a huge step into the US market and was recognized as trustworthy (even 2-year-olds are can be prescribed Epidiolex). Naturally, the sales are expected to skyrocket and reach $1 billion per year, or even $2 billion. By the way, GW Pharmaceuticals market cap is 5.131B.

So, everything seems to be going great, but… What the company did not prepare for, and it is a bit surprising bearing in mind their experience, is the huge demand for the new drug which has surpassed the expectations and caused the shares to drop by 3% (!). Which is worse, the doubt in their business management was triggered by a simple tweet of a dissatisfied father. It makes one wonder if GW Pharmaceuticals can rise to the challenge.

Taking everything into consideration, we believe that GW Pharmaceuticals’ future shines a bit more brightly than Aurora Cannabis’. The latter is definitely a huge producer and distributor, but GW Pharmaceuticals seem to be producing medical cannabis of such high quality that even the FDA had to approve of it. After all, the winners have always been those who were able to offer something unique, extraordinary and extremely high-quality, no matter the industry, and GW Pharmaceuticals appear to be one of them.

Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill For Cannabinoid Therapies

ISRAEL: Intec Pharma, a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced the results from a Phase I clinical trial of AP-CBD/THC, its Accordion Pill platform with cannabidiol (CBD) and tetrahydrocannabinol (THC), the two primary cannabinoids contained in Cannabis sativa.

“We’re excited about these encouraging results from our Phase 1 study of AP-CBD/THC as it shows the Accordion Pill platform is well suited to safely deliver CBD and THC with significant improvements in exposure compared with Sativex,” said Nadav Navon, Ph.D., Chief Operating Officer of Intec Pharma. “We are particularly pleased to see the reduction in THC metabolite, which tells us that the AP-CBD/THC avoided some of the hepatic first-pass metabolism of THC.”

The Phase I trial was a single-center, single-dose, randomized, three-way crossover study to compare the pharmacokinetics, safety and tolerability of two formulations of AP-CBD/THC with Sativex in 21 normal healthy volunteers. Sativex is a commercially available oral buccal spray containing CBD and THC[1].

The study results showed that AP-CBD/THC had significant improvements in exposure of CBD (290% – 330%) and THC (25% – 50%) compared with Sativex. The median time of peak concentration was 2-3 times longer than Sativex and absorption was significantly higher. Importantly, the formation of THC metabolites were meaningfully reduced (>25%) and AP-CBD/THC was found to be safe and well tolerated with no serious adverse events reported.

“This study further affirms the value of our Accordion Pill platform as a safe and effective drug delivery platform,” said Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma. “We plan to review these data in the coming weeks to determine the next steps in developing our AP-CBD/THC program and plan to announce the next steps in the clinical development of this exciting program by year end.”

The Cannabis sativa plant is used for the treatment of chronic pain and a variety of other indications. Previous clinical studies conducted using the whole plant or specific extracts generated evidence of the cannabis analgesic activity. Furthermore, extracts containing known amounts of the active plant driven compounds (mainly THC and CBD) or diverse synthetic THC derivatives are thought to be promising treatments for painful conditions that do not respond properly to currently available treatments, such as chronic, neuropathic and inflammatory pain[2],[3].

AP-CBD/THC holds the potential to address several major drawbacks of current methods of use and treatment with cannabis and cannabinoids, such as short duration of effect, delayed onset, variability of exposure, variability of the administered dose and adverse events that correlate with peak levels. AP-CBD/THC is designed to extend the absorption phase of CBD and THC, resulting in more consistent levels for an improved therapeutic effect.

The cannabis market has significant commercial potential and is projected to represent approximately 10% of the specialty pharmaceutical market over the next five years, or a market of at least $20 billion[4]. According to Global Data, in 2016 the global low back pain drug market was $6.2 billion and the global Fibromyalgia drug market was $1.8 billion.

Marijuana’s Promise Of Profit Remains Elusive (For Now)

NEW YORK: Excitement surrounding medical marijuana led to a significant run-up in GW Pharmaceuticals‘ share price earlier this year, but based on the company’s recently announced quarterly and fiscal full-year earnings results, the promise of marijuana profit remains far off in the distance.

Planning for the future

That’s because GW Pharma has only one marketed marijuana derived therapy, Sativex, on the market, and Sativex, which is used to treat multiple sclerosis spasticity, has yet to win the FDA go-ahead for use in United States. As a result, sales of Sativex, which come primarily from European markets, total just $2 million in the quarter ending June and were small enough for the full fiscal year ending September that the company didn’t bother breaking them out in its quarterly earnings press release.

Instead, the company focused the bulk of its earnings report on the promising opportunity for its marijuana-based medicine across various indications and a slate of trials spanning cancer pain, epilepsy, schizophrenia, and even diabetes.

Those trials are all ongoing, so investors will need to rely on past trial data to make judgments on whether or not the market demand for GW Pharma’s medicine will justify the company’s $1.27 billion market cap.

GW Pharmaceuticals Closes U.S. Public Offering; Cannabis-Based Medicines Progress

NORTH CAROLINA:  Yesterday, Salisbury, UK-based GW Pharmaceuticals plc announced the closing of its public offering of 1.7 million American Depositary Shares on the NASDAQ Global Market. When taken together with the full exercise of options for another 255,000 ADSs by the underwriters at $86.83/ADS, the offering totaled $169.8 million.

Although some of the ADRs were sold by current shareholders, the company still grossed $126.3 million before discounts and expenses.

The funds come at a time when its flagship product,Sativex®, garnered a FDA Fast Track designation–after its approval in several other countries as early as 2005–and its Epidiolex® cannabidiol (CBD) formulation received orphan drug designation for severe, intractable epilepsy syndromes in infants and young children.

Coincident with the conclusion of GW’s stock offering yesterday, the North Carolina State House of Representatives is advancing a bill that would explicitly permit patients and their families to obtain a CBD-enriched oil (10% or more) with no more than 0.3% THC, the primary psychoactive constituent.

7 Things You Need To Know About Sativex

GREAT BRITAIN: Many are starting to hear about a marijuana-based pharmaceutical called Sativex. The drug, which comes as an oral spray, has already been approved in 24 countries as a treatment for multiple sclerosis.

While yet to be approved in the United States, Sativex is legally available in countries like Canada, Australia, Britain and, most recently, France. But the drug has generated a lot of talk in the U.S., largely due to its role in the medical marijuana debate.

According to a recent interview with GW Pharmaceuticals, the company behind the drug, Sativex could be just months away from FDA approval. And if that happens, there’s no doubt the debate over marijuana as a medicine will only intensify.